Genesystem

At a glance

Genesystem filed 56 disclosures in the last 12 months, including 8 5% holder, 4 m&a, 3 insider and 3 issuance. The most recent key filing was on Oct 15.

Revenue for 2025 was ₩381.4M, down 68.4% on 2024. It made an operating loss of ₩9.7B. Debt was 86% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩761.5M and operating loss of ₩2.6B.

The 2025 annual report lists 52 employees with an average tenure of 5 years and average pay of ₩58M, #1073 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩118.3M each on average. It paid no cash dividend for 2025. 서유진 and related parties held 18.67% at year end.

From the 2025 annual report

Staff: 52 (24 men, 28 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩3.3B. Directors and auditors: 5, paid ₩591.4M in total.

No cash dividend was paid for 2025.

Largest shareholder

서유진 holds 15.52%; with 4 related parties the group holds 18.67% of common shares at year end (from 18.39% at the start of the year).

Auditor: 삼화회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary